Gorjan Hrustanovic
Managing Director @ Biotechnology Value Fund
San Francisco, United States
Gorjan Hrustanovic is a Managing Director at Biotechnology Value Fund. He attended University of California, San Francisco.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Gorjan Hrustanovic invests in
Stages Gorjan Hrustanovic invests in
Countries Gorjan Hrustanovic invests in
Investment Focus
Industry
- Biotechnology 5 (63%)
- Health Care 4 (50%)
- Medical 2 (25%)
- Therapeutics 2 (25%)
- Biopharma 1 (13%)
Stage
- Series A 3 (38%)
- Series B 2 (25%)
- Post-IPO Equity 1 (13%)
- Venture - Series Unknown 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Expedition Therapeutics
|
Expedition Therapeutics operates as an unincorporated association. | $165M / Series A / Oct 09, 2025 | |
Olema Oncology
|
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer.The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to designcompounds that are superior to both the current drugs and those in development.Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies. | $250M / Post-IPO Equity / Dec 02, 2024 | |
AltruBio
|
AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases.AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment ofcancer and immune-related inflammatory diseases.With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discovery and development of novel therapeutics for unmet medical needs.Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics.Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages. | $225M / Series B / May 21, 2024 | |
|
Olema Oncology
|
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer.The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to designcompounds that are superior to both the current drugs and those in development.Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies. | $130M / Post-IPO Equity / Sep 05, 2023 | |
Nimbus Therapeutics
|
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders. | $125M / Venture - Series Unknown / Sep 12, 2022 | |
|
Olema Oncology
|
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer.The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to designcompounds that are superior to both the current drugs and those in development.Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies. | $54M / Series B / Jul 22, 2020 | |
|
Olema Oncology
|
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer.The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to designcompounds that are superior to both the current drugs and those in development.Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies. | $6.1M / Series A / Aug 23, 2018 | |
Rain Oncology
|
Rain Therapeutics develops targeted therapies for patients with cancer. We begin by identifing cancers with a single, and clear, oncogenic driver and evaluating sub-populations of cancer populations with an unmet need, where standards of care are ineffective. Our global scientific and thought-leader network drives our asset and technologyidentification to match these cancers with small molecule therapeutics targeted at treating specific cancer mutations. | $18.4M / Series A / May 21, 2018 |
Co-Investors
About Biotechnology Value Fund
Biotechnology Value Fund is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments.Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies while performing rigorous diligence and on-going monitoring of itsinvestments.BVF is committed to working with its portfolio companies as partners in their successes.
Biotechnology Value Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Gorjan Hrustanovic
Managing Director
|
|||
James Kratky
Chief Financial Officer, Chief Compliance Officer
|
|||
Matthew Perry
Portfolio Manager
|
|||
Michael Murray
Managing Director
|
|||
Sam Huang
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Gorjan Hrustanovic invest in?
Gorjan Hrustanovic invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Gorjan Hrustanovic last invest?
The most recent investment recorded for Gorjan Hrustanovic closed in Oct 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
